Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • erdafitinib

    - PMLiVE

    Pfizer’s PADCEV gets FDA approval for bladder cancer

    Bladder cancer affects more than 614,000 people globally each year

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    John Morikis joins Johnson & Johnson’s board of directors

    Morikis was previously Chairman, President and CEO at Sherwin-Williams

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

    An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

    - PMLiVE

    AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer

    More than 35,000 people in five major European countries were treated for the disease last year

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    - PMLiVE

    AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

    More than 614,000 cases of bladder cancer are diagnosed globally every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links